BMS-646256 in Obese and Overweight Type 2 Diabetics

PHASE2/PHASE3WithdrawnINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

March 31, 2008

Study Completion Date

June 30, 2010

Conditions
Obesity and Type 2 Diabetes
Interventions
DRUG

ibipinabant

oral, tablet, once daily

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Solvay Pharmaceuticals

INDUSTRY